Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H12N2O7P2 · H2O
CAS Number:
Molecular Weight:
340.16
UNSPSC Code:
12352106
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Product Name
Minodronic acid monohydrate, ≥98% (HPLC)
InChI
1S/C9H12N2O7P2.H2O/c12-9(19(13,14)15,20(16,17)18)5-7-6-10-8-3-1-2-4-11(7)8;/h1-4,6,12H,5H2,(H2,13,14,15)(H2,16,17,18);1H2
SMILES string
OC(P(O)(O)=O)(P(O)(O)=O)CC1=CN=C2N1C=CC=C2.O
InChI key
GPAPAOGRNKUFGH-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
0.1 M NaOH: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
Related Categories
Biochem/physiol Actions
Bone resorption inhibitor; inhibitor of farnesyl diphosphate synthase
Minodronate is a third-generation bisphosphonate used clinically alone or in combination to treat osteoporosis. It is an inhibitor of farnesyl diphosphate synthase that acts as a bone resorption inhibitor.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Motoaki Yasukawa et al.
Anticancer research, 36(11), 5883-5886 (2016-10-30)
Non-small cell lung carcinoma (NSCLC) is one of the leading causes of cancer-related death worldwide. Recent studies showed that nitrogen-containing bisphosphonates (N-BPs) directly and indirectly prevent proliferation, induce apoptosis, and inhibit metastasis of various types of cancer cell. In order
Shinichi Nakatoh
Journal of bone and mineral metabolism, 36(2), 221-228 (2017-03-16)
This study reveals the changes in bone mineral density (BMD), the turnover rate, and the balance [multiple of median formation/multiple of median resorption (MoMf/MoMr)] affected by the selection of different bone resorption inhibitors after 24-month daily teriparatide (20 µg/day) administration.
Tsuyoshi Ohishi et al.
Endocrine research, 42(3), 232-240 (2017-03-21)
Monthly regimen of minodronate for osteoporosis more than two years has not been reported yet. The aim of this study is to elucidate the effect of monthly minodronate (M-MIN) on bone mineral density (BMD) and serum pentosidine (Pen) during 27
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service